KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.

Lisa A Kachnic, Jennifer Moughan, Theodore S Hong, Michael G Haddock, Naeem Tahir, Harry H Yoon, Dayssy A Diaz, Carryn M Anderson, Samantha A Seaward, Christopher E Lominska, Paul E O'Brien, Yuhchyau Chen, Jonathan C Salo, Alfred D Christie, Jennifer A Dorth, Raid M Aljumaily, Elizabeth M Gore, Kathryn A Winter, Howard P Safran, Benjamin Movsas

Cancer 132(6) e70345

PMID41808581
PMCIDPMC13321207
DOI10.1002/cncr.70345
发表日期2026-03-11
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:瀑布图。
摘要

摘要

BACKGROUND: NRG/RTOG 1010 evaluated trastuzumab added to trimodality therapy for HER2+ localized esophageal adenocarcinoma (EAC) management. Secondary PRO objectives assessed improvement in the FACT-Esophageal Cancer Subscale (ECS), version 4, with trastuzumab, and if improved ECS correlated with pathologic complete response (pCR). METHODS: Patients were randomized to weekly paclitaxel/carboplatin/radiation (chemoradiation, CRT) followed by surgery ± trastuzumab (CRT + Tras). Disease-free survival (DFS) was the primary end point. The projected PRO sample size of 158 patients, based on an 80% participation rate of the DFS primary endpoint sample size of 197 HER2+ patients, would provide ≥ 89% power to detect ≥25% increase in the proportion of CRT + Tras patients with ECS improvement from baseline to 6-8 weeks post-CRT; one-sided α = 0.05, using a χ2 test. Improvement in ECS and its swallowing index (SI) and eating index (EI) was defined as 5-, 2-, and 2-point increases, respectively, from baseline to 6-8 weeks post-CRT. Univariate logistic regression was assessed if pCR was associated with improved ECS. RESULTS: From 2010 to 2015, 203 HER2+ patients were randomized and 194 were eligible. Of 171 PRO consenting patients, the ECS was completed by 162 (95%) at baseline, 108 (64%) 6-8 weeks, 82 (49%) 1 year, and 55 (33%) at 2 years. The proportion of patients with an improvement in 6-8 weeks ECS was higher on the CRT + Tras arm (46% vs. 38%), although not significantly different (p = .39). There was no correlation between pCR and ECS scores at 1 year, with 39% and 37% of pCR and non-pCR patients, respectively, having improved 1-year ECS scores. CONCLUSIONS: The addition of trastuzumab to CRT for localized HER2+ EAC did not improve PROs.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Mean FACT-E ECS, SI, and EI Scores by Treatment Arm Abbreviations: FACT-E, Functional Assessment of Cancer Therapy for Esophageal Cancer; ECS, Esophageal Cancer Subscale; SI, Swallowing Index; EI, Eating Index; CRT, chemoradiation; Tras, trastuzumab
非 KM Figure
Figure 2Figure 2. Categorization of the FACT-E ECS Change from Baseline by Treatment Arm Abbreviations: FACT-E, Functional Assessment of Cancer Therapy for Esophageal Cancer; ECS, Esophageal Cancer Subscale; CRT, chemoradiation; Tras, trastuzumab
非 KM Figure
Figure 3Figure 3. Waterfall Plot of Difference* in Treatment Arms for Mean Change in Individual PRO Items of the FACT-E ECS from Baseline to 6–8 Weeks *Difference = (CRT+Tras mean change – CRT mean change); Higher mean change: ECS item better at 6–8 weeks in the CRT+Tras arm than the CRT arm Lower mean change: ECS item worse at 6–8 weeks in the CRT+Tras arm than the CRT arm Abbreviations: PRO, patient-reported outcomes; FACT-E, Functional Assessment of Cancer Therapy for Esophageal Cancer; ECS, Esophageal Cancer Subscale; CRT, chemoradiation; Tras, trastuzumab Swallowing Index; EI, Eating Index
非 KM Figure